An evaluation of combinations of diaziquone, etoposide and mitoxantrone in the treatment of adults with relapsed or refractory acute myeloid leukemia: Results of 8722, a randomized phase II study conducted by Cancer and Leukemia Group B

Leukemia

Volumn 12, Issue 2, 1998, Pages 139-143

  Lee, E J ^a   George, S L ^b   Amrein, P C ^c   Paciucci, P A ^d   Allen, S L ^e,f   Schiffer, C A ^a,g  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^f CALGB   (United States)

^g HARPER UNIVERSITY HOSPITAL   (United States)

Author keywords

Acute myeloid leukemia; Chemotherapy; Diaziquone; Etoposide; Mitoxantrone

Indexed keywords

DIAZIQUONE; ETOPOSIDE; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; BLEEDING; CANCER MORTALITY; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA REMISSION; LIVER TOXICITY; LUNG TOXICITY; MAJOR CLINICAL STUDY; NAUSEA; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; VOMITING;

EID: 0031910149     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2400905     Document Type: Article

References (27)

1. Mayer RJ, Davis RB, Schiffer CA et al. Intensive post-remission chemotherapy in adults with acute myeloid leukemia. New Engl J Med 1994; 331: 896-903.
2. Schiffer CA. Hematopoietic growth factors as adjuncts to the treatment of acute myeloid leukemia. Blood 1996; 88: 3675-3685.
3. Rowe JM, Anderson JW, Mazza JJ et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood 1995; 86: 457-462.
4. Stone RM, Berg DT, George SL et al. Granulocyte-macrophage colony stimulating factor following initial chemotherapy for patients at least 60 years old with primary acute myeloid leukemia: a double-blinded, randomized study. New Engl J Med 1995; 332:1671-1677.
5. Heil G, Hoelzer D, Sanz MA, Lechner K, Yin JL, Papa G, Noens L, Ho J, O'Brien C, Matchman J, Barge A. Results of a randomized, double-blind placebo controlled phase III study of filgrastim in remission induction and early consolidation therapy for adults with de novo acute myeloid leukemia. Blood 1995; 86: 267a.
6. Godwin JE, Kopecky KJ, Head DR, Hynes HE, Balcerzak SP, Appelbaum FR. A double blind placebo controlled trial of G-CSF in elderly patients with previously untreated acute myeloid leukemia. Blood 1995; 86: 434a.
7. Ohno R, Tomonaga M, Kobayashi T, Kanamaru A, Shirakawa S, Masaoka T, Omine M, Oh H, Nomura T, Sakai Y et al. Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. New Engl J Med 1990; 323: 871-877.
8. Dombret H, Chastang C, Fenaux P, Reiffers J, Bordessoule D, Bouabdallah R, Mandelli F, Ferrant A, Auzanneau G, Tilly H et al. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. New Engl J Med 1995; 332: 1678-1683.
9. Lee EJ, Van Echo DA, Egorin MJ, Nayar MSB, Schulman P, Schiffer CA. Diaziquone given as a continuous infusion is an active agent for relapsed adult acute non-lymphocytic leukemia. Blood 1986; 67: 182-187.
10. Schulman P, Davis R, Lee E, Ellerton J, Staszweski H for Cancer and Leukemia Group B. Phase II study of continuous infusion aziridinylbenzoquine (AZQ/Diaziquone) (NSC No. 182986) in relapsed/refractory acute non-lymphocylic leukemia. Cancer Treat Rep 1987; 71: 755-757.
11. Lee EJ, Reck K, Schiffer CA. Continuous infusion diaziquone and etoposide: a phase I study in adult patients with acute leukemia. Leukemia 1990; 4: 189-192.
12. Paciucci PA, Davis RB, Holland JF, Martelo O, Schiffer CA. Mitoxantrone and constant infusion etoposide for relapsed and refractory acute myelocytic leukemia. American Journal of Clinical Oncology 1990; 13: 516-519.
13. Amrein PC, Davis RB, Mayer RJ, Schiffer CA. Treatment of relapsed and refractory acute myeloid leukemia with diaziquone and mitoxantrone: a CALGB phase I study. Am J Hematol 1990; 35: 80-83.
14. Ho AD, Lipp T, Ehninger C, Illiger HJ, Meyer P, Freund M, Hunstein W. Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia-an active and well-tolerated regimen. J Clin Oncol 1988; 6: 213-217.
15. Pocock SJ. Clinical Trials: A Practical Approach. John Wiley: New York, 1983.
16. Weiss RB, Vogelzang NJ, Peterson BA et al. A successful system of scientific data audits for clinical trials. A report from the Cancer and Leukemia Group B. J Am Med Assoc 1993; 270: 459-474.
17. Cheson BD, Cassileth PA, Head DR, Schiffer CA, Bennett JM, Bloomfield CD, Brunning R, Gale RP, Grever MR, Keating MJ, Sawitsky A, Stass S, Weinstein H, Woods WG. Report to the NCI-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 1990; 8: 813-819.
18. Simon R, Wittes RE, Ellenberg SS. Randomized phase II clinical trials. Cancer Treatment Rep 1985; 69: 1375-1381.
19. Mehta CR, Patel NR. A network algorithm for performing Fisher's exact test in rxc contingency tables. J Am Stat Assoc 1983; 78: 427-434.
20. Armitage P, Berry G. Statistical Methods in Medical Research, 2nd edn, Blackwell Scientific: Oxford, 1987, pp 363-365.
21. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 347-381.
22. Peto R, Pike ME, Armitage P. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977; 35: 1-39.
23. Altman DC. Practical Statistics for Medical Research. Chapman and Hall: London, 1991, pp 230-235.
24. Brookmeyer R, Crowley J. A confidence interval for the medical survival time. Biometrics 1982; 38: 29-41.
25. Knauf WU, Berdel WE, Ho AD, Kreuser ED, Thiel E. Combination of mitoxantrone and etoposide in the treatment of myelodysplastic syndromes transformed into acute myeloid leukemia. Leuk Lymphoma 1994; 12: 421-425.
26. Schiffer CA, Davis RB, Schulman P, Cooper B, Coyle T, Lee EJ, Delduca V for the CALGB. Intensive post remission therapy of acute myeloid leukemia with cytoxan/etoposide (CY/VP16) and diaziquone/mitoxantrone (AZQ/Mitox). Blood 1991; 78: 460.
27. Moore JO, Dodge RK, Amrein PC, Kolitz J, Lee EJ, Powell B, Godfrey S, Robert F, Schiffer CA. Granulocyte colony stimulating factor (Filgrastim) accelerates granulocyte and platelet recovery following intensive post-remission chemotherapy for acute myeloid leukemia with aziridinylbenzoquinone (AZQ) and mitoxantrone: Cancer and Leukemia Group B study 9022. Blood 1997; 89: 780-788.